Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Tango Therapeutics Inc (TNGX)

NASDAQ: TNGX · Pharmaceutical Preparations · Boston, MA

Our rating: Cautious

Cautious reaffirmed at $24.30, moderate conviction, November 10, 2026.

Breaks if: The Cautious call is wrong if TNGX reports annual revenue above $95M in the next full fiscal-year filing — a 53% step-up from $62M that would imply a new and durable source of milestone or royalty income, reframing revenue quality — or if the stock holds above $31 for 30 consecutive trading days within twelve months, signaling pipeline de-risking at a scale not visible in today's filings.

Key figures

Market value$3.7B
Revenue, last 12 months$0.00
Net income, last 12 months−$208M
Free cash flow, last 12 months−$150M
Price to earningsn/a
Free cash flow yield−4.1%
Dividend yield0.0%
Operating marginn/a
Return on equity−36.5%
Beta to the S&P 5001.46
Volatility, annualized102.9%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$0.00−100.0%$-0.39−$37M
June 30, 2026$0.00−100.0%$-0.37−$39M
March 31, 2026$0.00−100.0%$-0.32−$44M
December 31, 2025$0.00−100.0%$-0.30−$30M
September 30, 2025$54M363.6%$0.13−$31M
June 30, 2025$3M−84.0%$-0.35−$37M
March 31, 2025$5M−16.7%$-0.36−$42M
December 31, 2024$4M−24.2%$-0.34−$37M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

34 ledger entries and 22 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.